Qube Research & Technologies (QRT)
SPRY icon

Qube Research & Technologies (QRT)’s ARS Pharmaceuticals SPRY Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,034,798
Closed -$10.4M – 4058
2025
Q3 		$10.4M Buy
+1,034,798
New +$14.9M 0.01% 1299
2025
Q1 		– Sell
-130,289
Closed -$1.37M – 3860
2024
Q4 		$1.37M Buy
130,289
+90,593
+228% +$1.27M ﹤0.01% 2036
2024
Q3 		$576K Buy
+39,696
New +$472K ﹤0.01% 2221
2024
Q2 		– Sell
-12,633
Closed -$129K – 4666
2024
Q1 		$129K Buy
+12,633
New +$94.2K ﹤0.01% 3208
2023
Q2 		– Sell
-77,369
Closed -$504K – 2974
2023
Q1 		$504K Buy
77,369
+48,532
+168% +$373K ﹤0.01% 1563
2022
Q4 		$246K Buy
28,837
+12,412
+76% +$80.5K ﹤0.01% 1725
2022
Q3 		$87K Sell
16,425
-1,441
-8% -$7.1K ﹤0.01% 2010
2022
Q2 		$76K Buy
+17,866
New +$62.3K ﹤0.01% 2029
2021
Q1 		– Sell
-19,484
Closed -$903K – 2385
2020
Q4 		$903K Buy
+19,484
New +$651K 0.01% 911

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s SPRY Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 1,034,798 shares — an estimated $10.4M sold.

Qube Research & Technologies (QRT) first reported a position in SPRY in Q4 2020 and held it in 9 quarters. The position peaked at $10.4M in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1,034,798 ARS Pharmaceuticals shares in Q4 2025, an estimated $10.4M.
  • Qube Research & Technologies (QRT) first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s ARS Pharmaceuticals position peaked at $10.4M in Q3 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.